NCT02429570

Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary

Pilot Study of Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Cancer that has spread to the brain, or brain metastasis, is difficult to treat. Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the laboratory. This medicine has been used in the past to treat pain. But, in this study, it will be used to prevent new brain metastasis. This is the first time that meclofenamate will be used in patients with brain metastasis. This is a pilot study which means that the purpose of this study is to determine if a larger clinical trial of meclofenamate is possible in patients with brain metastasis. This study also aims to find out what effects, good and/or bad meclofenamate has on the patient and the cancer that has spread to the brain. The investigators also want to learn more about potential effects that this drug may have in the digestive system.

Conditions

• Recurrent Brain Metastases
• Progressive Brain Metastases

Interventions

Type	Name	Description
DRUG	Meclofenamate

Timeline

• Start date: 2015-04-22
• Primary completion: 2027-04-01
• Completion: 2027-04-01
• First posted: 2015-04-29
• Last updated: 2026-03-17

Locations

7 sites across 1 country: United States